Related Experiment Videos
Hypocomplementemia with low C1s-C1 inhibitor complex in systemic lupus erythematosus
Insights
Complement activation, measured by C1s-C1 inhibitor complex, is often transient in systemic lupus erythematosus patients with hypocomplementemia. This finding offers insights into lupus complement pathways.
Area of Science:
- Immunology
- Rheumatology
- Clinical Chemistry
Background:
- Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by immune system dysregulation.
- Complement system activation is implicated in SLE pathogenesis.
- Assessing complement activation markers is crucial for understanding disease activity.
Purpose of the Study:
- To investigate the correlation of C1s-C1 inhibitor complex levels with other complement components (C3, C4, C4a desarginine) and immune complexes in SLE patients.
- To evaluate the dynamic changes of C1s-C1 inhibitor complex in patients with hypocomplementemia over time.
- To determine the relationship between C1s-C1 inhibitor complex and clinical parameters in SLE.
Main Methods:
- Analysis of serum and plasma samples from 45 SLE patients.
- Measurement of C1s-C1 inhibitor complex, C3, C4, C4a desarginine, and staphylococcal protein A-bound immune complexes.
- Serial sampling over 6 months for 24 patients.
- Statistical correlation analysis.
Main Results:
- Significant correlations were found between C1s-C1 inhibitor complex and CH50, C4, and C4a desarginine.
- Complement activation, indicated by C1s-C1 inhibitor complex, was often transient in SLE patients with persistent hypocomplementemia.
- Staphylococcal protein A-bound immune complexes showed no correlation with complement assays.
- Abnormal C1s-C1 inhibitor complex levels were observed in pregnant SLE patients with normal complement levels.
Conclusions:
- Complement activation, assessed via C1s-C1 inhibitor complex, is frequently a transient event in SLE patients experiencing hypocomplementemia.
- C1s-C1 inhibitor complex serves as a valuable marker for monitoring complement activation dynamics in SLE.
- Further research is warranted to explore the clinical implications of transient complement activation in SLE management.
Abstract:
Ninety-three serum and plasma samples from 45 patients with systemic lupus erythematosus were analyzed for the complex formed by C1s and its inhibitor, as well as for C3, C4, C4a desarginine, and staphylococcal protein A-bound immune complexes. There were statistically significant correlations between C1s-C1 inhibitor complex and CH50, between C1s-C1 inhibitor complex and C4, and between C1s-C1 inhibitor complex and C4a desarginine. Serial studies were performed on 24 patients over a period of 6 months. Seven of 21 patients with hypocomplementemia had persistently normal levels of C1s-C1 inhibitor complex, 7 had transiently abnormal levels of C1s-C1 inhibitor complex, and 7 had sustained abnormal levels of C1s-C1 inhibitor complex. Two of 3 pregnant patients with normal levels of complement had abnormal levels of C1s-C1 inhibitor complex. Staphylococcal protein A-bound immune complexes demonstrated no correlation with any of the complement assays. Complement activation, as measured by C1s-C1 inhibitor complex, is often a transient phenomenon in systemic lupus erythematosus patients with persistent hypocomplementemia.